Current state of art for transplantation paradigms in peripheral T-cell lymphomas.

about

Current state of art for transplantation paradigms in peripheral T-cell lymphomas.

Item

http://www.wikidata.org/entity/Q38132821

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Current state of art for transplantation paradigms in peripheral T-cell lymphomas.

@en

type

Item

label

Current state of art for transplantation paradigms in peripheral T-cell lymphomas.

@en

prefLabel

Current state of art for transplantation paradigms in peripheral T-cell lymphomas.

@en

P1476

Current state of art for transplantation paradigms in peripheral T-cell lymphomas

@en

P2093

Giulia Perrone

http://www.w3.org/2001/XMLSchema#string

Lucia Farina

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation

Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma

Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study

Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.

Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant.

Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma.

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

P304

465-474

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17474086.2013.814437

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lucia Farina

Paolo Corradini

Giulia Perrone

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23991932

http://www.w3.org/2001/XMLSchema#string